Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HIV-specific CD8 cells are an autologous cell therapy being developed by Guangzhou 8th People's Hospital for the treatment of HIV infection. The therapy involves the isolation, expansion, and transfusion of CD8+ T cells (cytotoxic T lymphocytes) that are specifically primed to recognize and eliminate HIV-infected cells. The primary objective of this intervention is to reconstitute the patient's cellular immune response against the virus, which is typically compromised or exhausted in chronic HIV infection. By increasing the frequency and activity of these specific effector cells, the therapy aims to achieve durable control of viral replication, potentially allowing for the discontinuation of highly active antiretroviral therapy (HAART) and moving toward a functional cure for AIDS.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on HIV-specific CD8 cells (Guangzhou 8th People's Hospital).